scholarly article | Q13442814 |
P50 | author | Sérgio Luiz Dalmora | Q91040954 |
P2093 | author name string | Bruna Xavier | |
Maurício Elesbão Walter | |||
Rafaela Ferreira Perobelli | |||
Francielle Santos da Silva | |||
P2860 | cites work | Properties and use of botulinum toxin and other microbial neurotoxins in medicine | Q23833526 |
Assessing the Immunogenicity of Biopharmaceuticals | Q26751485 | ||
Characterizing biological products and assessing comparability following manufacturing changes. | Q30344134 | ||
Quantitative mass spectrometry for bacterial protein toxins--a sensitive, specific, high-throughput tool for detection and diagnosis. | Q33845862 | ||
Clinical uses of botulinum neurotoxins: current indications, limitations and future developments | Q36395728 | ||
Progress in cell based assays for botulinum neurotoxin detection | Q36818335 | ||
Bioassays for evaluation of medical products derived from bacterial toxins | Q38014992 | ||
Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays | Q38056721 | ||
Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates | Q38078925 | ||
The Expanding Therapeutic Utility of Botulinum Neurotoxins. | Q55105284 | ||
Cell-Based Reporter Release Assay to Determine the Potency of Proteolytic Bacterial Neurotoxins | Q58762547 | ||
Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the Internationa | Q73071507 | ||
Validation of in vitro assays for botulinum toxin: a case study | Q73194608 | ||
Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methods | Q90503604 | ||
Methods and difficulties in detection of Clostridium botulinum and its toxins. | Q38203898 | ||
Botulinum toxin A, brain and pain | Q38219087 | ||
Botulinum neurotoxins: genetic, structural and mechanistic insights. | Q38224215 | ||
The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins | Q38340501 | ||
Analysis of streptokinase by validated liquid chromatography methods and correlation with an in vitro bioassay | Q38435106 | ||
Botulinum toxin: State of the art. | Q38668149 | ||
Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line | Q39159847 | ||
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology | Q39207459 | ||
Development of a Cell-Based Functional Assay for the Detection of Clostridium botulinum Neurotoxin Types A and E. | Q39243951 | ||
Correlation of liquid chromatographic and biological assay for potency assessment of filgrastim and related impurities | Q39703051 | ||
A chip-based assay for botulinum neurotoxin A activity in pharmaceutical preparations | Q41448985 | ||
The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. | Q42915094 | ||
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products | Q43185582 | ||
A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A. | Q43999920 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | toxicology | Q7218 |
reversed-phase chromatography | Q645497 | ||
size-exclusion chromatography | Q1617865 | ||
P304 | page(s) | 35 | |
P577 | publication date | 2019-01-12 | |
P1433 | published in | Toxins | Q15724569 |
P1476 | title | Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays | |
P478 | volume | 11 |
Q91994510 | Rapid Detection of Botulinum Neurotoxins-A Review | cites work | P2860 |
Search more.